此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region (ASC4Young)

2026年11月9日 更新者:Novartis Pharmaceuticals

ASC4Young: Real-World Study of Asciminib Safety and Efficacy in Young Adults With Chronic Myeloid Leukemia in the Gulf Region

The aim of this study is to evaluate the real-world effectiveness and safety of asciminib among young adults with chronic myeloid leukemia (CML) across the Gulf region. The data source for this study will consist of routinely collected clinical information documented within the electronic health records (EHR) of participating centers.

研究概览

地位

尚未招聘

研究类型

观察性的

注册 (估计的)

80

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:Novartis Pharmaceuticals

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 99年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

CML patients who initiate asciminib between 01 May 2023 and 31 May 2026 in participating centers across the Gulf region.

描述

Inclusion Criteria

  • Confirmed diagnosis of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP)
  • Adult patients aged ≥ 18 years at the index date (or adult as defined by applicable national regulations)
  • Documented exposure to asciminib during the identification period (May 2023 to May 2026)
  • Provision of signed informed consent for secondary use of data, or an ethics committee-approved waiver of consent, where applicable (including for deceased patients or where data were previously collected within the EHR system)

Exclusion Criteria

  • Patients who do not meet the eligibility criteria specified above
  • Patients with insufficient medical record documentation to determine asciminib exposure or key study outcomes

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:RETROSPECTIVE

队列和干预

团体/队列
Young Adults Cohort

CML patients aged ≤ 40 years at the first documented asciminib administration.

Older Adults Cohort

CML patients aged > 40 years at the first documented asciminib administration.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Major Molecular Response (MMR) Rate in Young Adults
大体时间:Approximately 12 Months

MMR is defined as a BCR::ABL1 level on the International Scale (BCR::ABL1 IS) ≤ 0.1%.

Approximately 12 Months

次要结果测量

结果测量
措施说明
大体时间
Incidence of Adverse Events (AEs)
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Treatment Interruptions Due to AEs
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Duration of Treatment Interruptions Due to AEs
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Time to Treatment Discontinuation due to Adverse Events (TTDAE)
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 10% After 3 Months of Treatment
大体时间:3 months
3 months
Proportion of Patients who Achieve an Early Molecular Response Milestone of BCR::ABL1 IS ≤ 1% After 6 Months of Treatment
大体时间:6 months
6 months
Number of Patients With Prior Tyrosine Kinase Inhibitor (TKI) Treatment
大体时间:Up to 12 months prior to Baseline
Up to 12 months prior to Baseline
Duration of CML at Time of Asciminib Treatment Initiation
大体时间:Baseline
Baseline
Asciminib Starting Dose
大体时间:Baseline
Baseline
Number of Treatment Interruptions
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Duration of Treatment Interruptions
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Patients by Reasons for Treatment Interruptions and Subsequent Treatment Switching
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Patients by Reason for Treatment Switch
大体时间:Approximately 3, 6, and 12 months
Approximately 3, 6, and 12 months
Number of Patients by Type and Severity of AEs
大体时间:Approximately 3, 6, and 12 months

Number of patients by type and severity of AEs including serious AEs and grade ≥ 3 AEs according to the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

Approximately 3, 6, and 12 months
Incidence of AEs Leading to Dose Modifications
大体时间:Approximately 3, 6, and 12 months

Dose modifications include treatment interruptions and dose reductions.

Approximately 3, 6, and 12 months
MMR in Patients Aged > 40 years
大体时间:Approximately 12 months

MMR is defined as BCR::ABL1 IS ≤ 0.1%.

Approximately 12 months
Rate of Deep Molecular Response
大体时间:Approximately 12 months

Deep molecular response includes:

  • Molecular response (MR) 4.0 (BCR::ABL1 IS ≤ 0.01%), and
  • MR4.5 (BCR::ABL1 IS ≤ 0.0032%), where available.
Approximately 12 months
Number of Patients With Dose Modifications
大体时间:Approximately 3, 6, and 12 months

Number of patients with dose modifications including up titration or dose reduction.

Approximately 3, 6, and 12 months
Number of Patients by Clinicopathological Characteristics
大体时间:Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline

Clinicopathological characteristics include:

  • Demographics (gender, ethnicity, nationality, smoking status, and insurance status)
  • Clinical presentation (signs and symptoms of disease)
  • Laboratory parameters (lipid panel, complete blood count, clinical chemistry, kidney, liver and pancreas function tests)
  • Molecular findings (BCR::ABL1 transcript types, additional cytogenetic abnormalities, and other reported mutations)
Up to 12 months pre-Baseline, Baseline, and approximately 3, 6 , and 12 months post-Baseline

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月1日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2026年6月26日

首先提交符合 QC 标准的

2026年6月26日

首次发布 (实际的)

2026年7月2日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅